lobbying_activities: 3055100

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
3055100	16e44621-e3cb-4945-a7a9-059a71a9252c	Q3	FORBES-TATE	400976792	AMGEN USA, INC.	2023	third_quarter	MED	Issues related to Biosimilars; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169).	HOUSE OF REPRESENTATIVES,SENATE	60000		0	0	2023-10-18T08:58:10-04:00